A cyberattack on Stryker wiped systems globally—what it reveals about hidden third-party risk in clinical trials and what biotech and pharma sponsors should do now.
Digital trust is the 2026 survival issue for life sciences. Explore five critical risks across AI, cloud, vendors, and governance—and how to address them.
Cut vendor evaluation time by 40-60% and pass inspection with zero vendor findings. Get the third-party risk management blueprint built for regulated life sciences.
Life sciences must modernize TPRM to safely scale AI and cloud tech. Discover 2026-ready risk strategies that enable innovation, compliance, and trust.
